Our Blog


RS Oncology, LLC, announces UK Medicines and Healthcare Regulatory Agency’s clinical trial acceptance of new drug, RSO-021, for treatment of Pleural Effusion and Mesothelioma


Cambridge, MA, October 1, 2021 ---- RS Oncology, LLC, (RSO) a biotechnical company focused on the treatment of patients with pleural effusion and mesothelioma, has announced acceptance of their novel drug, RSO-021, for use in a Phase 1/2 clinical trial by the Medicines and Healthcare Regulatory Agency in the UK.


RSO-021 therapy has proven to significantly reduce pre-clinically tumor burden in malignant mesothelioma and other cancer types by inhibiting three key enzymes in the antioxidant signaling network within the mitochondria. Covalent adduction of the active site of a key mitochondrial enzyme by RSO-021 inactivates the peroxidase activity of the enzymes leading to accumulation of hydrogen peroxide to levels incompatible with tumor cell survival, while preserving healthy normal cells. RSO-021 is being developed for the treatment of malignant pleural effusion (MPE) via intrapleural (IP) installation in patients suffering from mesothelioma, breast cancer and other indications causing MPE.


“We’re excited about RSO-021 as a novel metabolic therapy. This clinical trial is an important step in improving treatment for people living with this aggressive cancer,” said RS Oncology CEO and General Counsel, Jarrett Duncan. “RSO-021, the result of a collaboration between RSO, the University of Vermont Cancer Center and Wake Forest University School of Medicine, shows tremendous promise. The treatment has shown pre-clinical efficacy in nearly a dozen different indications, signifying broad applicability and therapeutic potential for cancer therapy.” “Most notably, treatments using this unique mechanism of action can be guided by a companion diagnostic, identifying patients with sufficiently dysregulated metabolic pathways prone to respond to this novel therapeutic approach.” added COO and Head of business development, George Naumov, Ph.D.



RS Oncology, LLC is a preclinical stage biotechnology company based in Cambridge, Massachusetts and London, UK with a mission to eradicate mesothelioma worldwide through new science and an innovative business model. The lead program is currently focused on development of novel therapies that modulate mitochondrial pathways that drive diseases of oxidative stress for treatment of malignant pleural effusion and malignant mesothelioma.

Updated: May 10

Today RS Oncology celebrates World Ovarian Cancer Day. We are hard at work with our partner, Azierta Foundation, to bring innovative treatment options for ovarian cancer patients worldwide.




Updated: Jan 22





Cambridge, Massachusetts and Madrid, Spain –September 30, 2019 – RS Oncology Ltd., Azierta Contract Scientific Support Consulting, S.L. and Azierta Foundation, announced today at the European Society for Medical Oncology (ESMO 2019) a partnership for co-development of RS Oncology’s novel therapeutic (PER-016) targeting mitochondria-based oxidative stress signaling pathways in ovarian cancer.

Azierta Contract Scientific Support Consulting, S.L. is a Science and Health consultancy firm committed to strengthening bonds between science and the business environment through the “Science to Business” concept. Azierta provides services in the field of medicinal products, Medical Devices, cosmetics, food supplements and biocides, offering complete solutions throughout products’ life cycle, from medical and regulatory support, to toxicology, manufacturing and distribution needs, market access and pharmacovigilance.

Mr. Ángel Navarro, Azierta’s CEO stated, “We are very excited to partner with RS Oncology in the development of this very exciting therapeutic. This is our first partnership and direct involvement in the development of an oncology asset through an innovative business model. We anticipate that RS Oncology's groundbreaking science will change drug development business norms and will result in novel therapies for patients.”

RS Oncology is a privately held pre-clinical biotechnology company based in Cambridge, Massachusetts. The company is currently developing a first-in-class oxidative stress modulator (PER-016) scheduled to enter Phase I clinical development in 1H20. This novel MOA targeted treatment approach is expected to have broad efficacy in various disease states of oxidative stress dysregulation. “This innovative partnership will allow us to expand into additional indications currently outside of our corporate strategy. This will ultimately speed up the process of reaching as many patients as possible sooner than anticipated with our exciting and potentially life-changing therapy,” stated Jarrett Duncan, CEO of RS Oncology.

More information about RS Oncology and Azierta Foundation can be found on: www.RSOncology.com and www.Azierta.eu and www.fundacionazierta.com

Media Contacts: RS Oncology Jarrett Duncan, CEO George Naumov, COO and Head of Business Development One Broadway, 14th floor Cambridge, MA 02142 info@rsoncology.com Email: j.duncan@rsoncology.com; g.naumov@rsoncology.com

Azierta Contract Scientific Support Consulting, S.L. and Azierta Foundation Ángel Navarro, Azierta’s CEO Eduardo Rodenas, VP Azierta Foundation Via de las Dos Castillas 33 Edificio 7 28224 Pozuelo de Alarcon (Madrid) Tel. 91 277 1076 info@azierta.com